Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Repurposing Services

Repurposing Services

Mechanism-driven repurposing and repositioning

Drug repurposing relies on establishing novel drug-target, target-disease or drug-disease associations. These relationships are often complex and require integration of heterogeneous information — chemical, biological, structural and clinical. Syngene combines multiple methods for learning from this diverse data to offer mechanism-of-action (MoA) based drug repurposing:

  • Drug centric: New indications for an existing molecule or failed molecule.
  • Target centric: New role for a target
  • Disease centric: Addressing an unmet medical need

Features

Our diverse computational expertise enables us to integrate multiple data sources and capture effects at many levels of a biological function – molecular to network and phenotypic inferences. This includes the following:

  • Integration of heterogeneous data to generate robust mechanism-of-action (MoA) hypotheses
  • Combining knowledge, gene signatures, protein networks and targeted mechanisms into a unified decision model
  • Making use of deep learning algorithms to extract higher order relationships

Repositioning in Animal Health

We create dossiers by assessing targets for their potential in repurposing drugs for use in animal health. We have experience in assessing human targets/therapeutics for bovine, porcine, feline, and canine diseases.

 Repositioning human/animal drugs to animal

The Syngene advantage

  • Deep computational capabilities: Deep computational biology, chemistry and data science expertise
  • Accelerated proof- of-concept: In silico, in vitro, and in vivo
  • Drug discovery expertise: Expertise in conventional drug discovery, PK/PD, dosing improves success rates
  • End-to-end solutions: Syngene can offer a complete preclinical/clinical package for your repurposing requirements

Your browser does not support this function.

To download, Please share your details

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements. To find out more, read our Privacy Policy and Cookies Policy.

To view or email, Please share your details view

To download, Please share your details